Drug intelligence / Profile preview

SM-337

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

SM-337 is a potent, orally bioavailable small molecule that functions as a Smac mimetic. It acts as an antagonist of caspase binding to inhibitor of apoptosis (IAP) family members, specifically targeting XIAP, cIAP1, and cIAP2. By antagonizing these IAP proteins, SM-337 promotes the activation of caspases and induces apoptosis in cancer cells. This mechanism makes it a candidate for anticancer therapy[2][1]. The compound is classified as synthetic organic.

Targets

BIRC2 (Cellular inhibitor of apoptosis protein 1)XIAPBIRC3 (Baculoviral IAP repeat-containing protein 3)

Beyond the preview

Go deeper on SM-337.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM-337.

Explore the full profile